Osteoporosis International

, Volume 21, Issue 7, pp 1277–1285

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial

  • R. Eastell
  • T. Lang
  • S. Boonen
  • S. Cummings
  • P. D. Delmas
  • J. A. Cauley
  • Z. Horowitz
  • E. Kerzberg
  • G. Bianchi
  • D. Kendler
  • P. Leung
  • Z. Man
  • P. Mesenbrink
  • E. F. Eriksen
  • D. M. Black
  • for the HORIZON Pivotal Fracture Trial
Original Article

DOI: 10.1007/s00198-009-1077-9

Cite this article as:
Eastell, R., Lang, T., Boonen, S. et al. Osteoporos Int (2010) 21: 1277. doi:10.1007/s00198-009-1077-9

Abstract

Summary

Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.

Introduction

To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.

Methods

In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.

Results

Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).

Conclusions

Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.

Keywords

Bisphosphonates Bone densitometry Bone QCT Clinical trials Osteoporosis 

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • R. Eastell
    • 1
    • 16
  • T. Lang
    • 2
  • S. Boonen
    • 3
  • S. Cummings
    • 4
  • P. D. Delmas
    • 5
  • J. A. Cauley
    • 6
  • Z. Horowitz
    • 7
  • E. Kerzberg
    • 8
  • G. Bianchi
    • 9
  • D. Kendler
    • 10
  • P. Leung
    • 11
  • Z. Man
    • 12
  • P. Mesenbrink
    • 13
  • E. F. Eriksen
    • 14
  • D. M. Black
    • 15
  • for the HORIZON Pivotal Fracture Trial
  1. 1.Academic Unit of Bone MetabolismUniversity of SheffieldSheffieldUK
  2. 2.Department of RadiologyUniversity of CaliforniaSan FranciscoUSA
  3. 3.Leuven University Centre for Metabolic Bone Diseases and Division of Geriatric MedicineKatholieke Universiteit LeuvenLeuvenBelgium
  4. 4.CPMC Research InstituteUniversity of CaliforniaSan FranciscoUSA
  5. 5.INSERM Research Unit 831 and University of LyonLyonFrance
  6. 6.Department of EpidemiologyUniversity of PittsburghPittsburghUSA
  7. 7.Savient PharmaceuticalsNew JerseyUSA
  8. 8.Argentine Reference Center in OsteoporosisHospital Ramos MejíaBuenos AiresArgentina
  9. 9.Division of RheumatologyLa Colletta HospitalGenoaItaly
  10. 10.Osteoporosis Research CentreVancouverCanada
  11. 11.Faculty of MedicineChinese University of Hong Kong, Prince of Wales HospitalHong KongChina
  12. 12.Centro TIEMPOUniversidad FavaloroBuenos AiresArgentina
  13. 13.Novartis Pharmaceuticals CorporationNew JerseyUSA
  14. 14.Department of EndocrinologyAker University HospitalOsloNorway
  15. 15.Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan FranciscoUSA
  16. 16.Metabolic Bone CentreSorby Wing, Northern General HospitalSheffieldUK

Personalised recommendations